UH Researchers Unveil Promising New Approach for Crohn's Disease Treatment

What To Know

University of Houston researchers report in Gastro Hep Advances that intrinsic defects in the intestinal epithelium — including chronic stress signaling and necroptosis — may drive Crohn’s disease.

In preclinical work using patient-derived intestinal organoids, the team tested repurposing two FDA-approved cancer kinase inhibitors, pazopanib and ponatinib, at low doses to block stress pathways, promote epithelial survival and regeneration, and reduce inflammation.

These results come from laboratory (preclinical) models rather than completed patient trials. The work suggests a shift in focus from only suppressing the immune response to restoring epithelial barrier function, and it uses organoids to model patient tissue.

Next steps would likely include formal clinical trials to assess safety and efficacy for Crohn’s patients; repurposed drugs can shorten timelines but still require careful testing in this new context.